DIETARY_SUPPLEMENT · Unmapped registry intervention
Ketogenic Diet
Find medicine records ·
Find other trials using this name
Clinical trial
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
NCT05090358
Drugs and interventions used in this trial
5 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DIETARY_SUPPLEMENT · Unmapped registry intervention
Low Carbohydrate Diet
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Alpelisib
Normalized identity: alpelisibView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Fulvestrant
Normalized identity: fulvestrantView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Canagliflozin
Normalized identity: canagliflozinView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPreventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Breast Cancer Stage IVunresolved
Metastatic Breast Cancerunresolved
Interventions
Ketogenic DietDIETARY_SUPPLEMENT
Low Carbohydrate DietDIETARY_SUPPLEMENT
AlpelisibDRUG · verified · RxNorm: alpelisib
FulvestrantDRUG · verified · RxNorm: fulvestrant
CanagliflozinDRUG · verified · RxNorm: canagliflozin
Sponsors & collaborators
Memorial Sloan Kettering Cancer Centerlead sponsor
New York Universitycollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05090358 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.